Sartorius Stedim BiotechSRTOY +1.89%82 Days Payable is 63.01 as of Mar. 2026, which is 4% above its 10-year median of 60.56. GuruFocus rates SRTOY with a GF Score™ of 82/100 and a GF Value™ of $23.65 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Sartorius Stedim Biotech ranks worse than 51.7% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Sartorius Stedim Biotech's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius Stedim Biotech Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius Stedim Biotech's Days Payable distribution charts can be found below:
* The bar in red indicates where Sartorius Stedim Biotech's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Sartorius Stedim Biotech's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sartorius Stedim Biotech (SRTOY) has a Days Payable of 63.01 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sartorius Stedim Biotech and its competitors. This is near median its historical median of 60.56. Over the past decade, Sartorius Stedim Biotech's Days Payable has ranged from 38.99 to 85.37. According to the industry distribution chart, Sartorius Stedim Biotech ranks #411 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 51.7%.
Is Sartorius Stedim Biotech's Days Payable too high?
Sartorius Stedim Biotech's current Days Payable of 63.01 is near median its 10-year median of 60.56. Over the past 10 years, this metric has ranged from a low of 38.99 to a high of 85.37. The Medical Devices & Instruments industry median Days Payable is 68.07. Sartorius Stedim Biotech's value of 63.01 is 7.4% below this industry median. Based on the distribution chart, Sartorius Stedim Biotech ranks #411 out of 795 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Sartorius Stedim Biotech has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius Stedim Biotech's Days Payable compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius Stedim Biotech ranks #411 out of 795 companies for Days Payable. This places Sartorius Stedim Biotech in the lower half of its industry. The industry median Days Payable is 68.07. Sartorius Stedim Biotech's value of 63.01 is 7.4% below this benchmark. Historically, Sartorius Stedim Biotech's own Days Payable has ranged from 38.99 to 85.37 over the past decade. While the company's 10-year median is 60.56 vs. the industry median of 68.07, Sartorius Stedim Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sartorius Stedim Biotech's current Days Payable of 63.01 is 7.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sartorius Stedim Biotech and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius Stedim Biotech's current Days Payable is 63.01, which is near median its own 10-year median of 60.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius Stedim Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sartorius Stedim Biotech (SRTOY) is currently considered Modestly Undervalued. The stock's GF Value™ is $23.65, compared to a current price of $20.47 — trading 13.4% below its estimated fair value. The current Days Payable is 63.01, which is near median its 10-year median of 60.56 and 7.4% below the Medical Devices & Instruments industry median of 68.07. Sartorius Stedim Biotech's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Sartorius Stedim Biotech (SRTOY), the current Days Payable is 63.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius Stedim Biotech (SRTOY) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued.
The current stock price of $20.47 is trading 13.4% below its estimated GF Value™ of $23.65.
GuruFocus considers Sartorius Stedim Biotech to be Modestly Undervalued.
Key valuation signals for SRTOY:
Days Payable: 63.01 (near median its 10-year median of 60.56)
GF Value™: $23.65 vs. price of $20.47 (13.4% below fair value)
Industry Position: 7.4% below the Medical Devices & Instruments median (#411 of 795)
No single metric tells the full story. See the SRTOY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
82GF Score
Get the complete analysis for SRTOY
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SRTOY has been successfully added to your 
